(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **P01627**

Total Pages in this Submission 166 c

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231						
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention optimized.						
invendon endued.						
POLY(2-OXAZOLINE) BIOMEDICAL DEVICES						
Jay F. Kunzler; Yu Chin Lai; Joseph A. McGee; Paul L. Valint, Jr.						
valint, Jr.						
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:						
Continuation Divisional Continuation-in-part (CIP) of prior application No.:						
Which is a:						
Continuation Divisional Continuation-in-part (CIP) of prior application No.:						
₩hich is a: Continuation □ Divisional □ Continuation-in-part (CIP) of prior application No.:						
Continuation Divisional Continuation-in-part (CIP) of prior application No.:						
Enclosed are:						
Application Elements						
Application Elements 1. Filing fee as calculated and transmitted as described below 2. Specification having 12 pages and including the following:						
2. Specification having pages and including the following:						
a. 🗷 Descriptive Title of the Invention						
b. Cross References to Related Applications (if applicable)						
c. Statement Regarding Federally-sponsored Research/Development (if applicable)						
d. Reference to Microfiche Appendix (if applicable)						
e. 🗵 Background of the Invention						
f. 🗷 Brief Summary of the Invention						
g. Brief Description of the Drawings (if drawings filed)						
h. 🗷 Detailed Description						
i. ☑ Claim(s) as Classified Below						
j. 🗷 Abstract of the Disclosure						

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P01627

Total Pages in this Submission 166

3.		Drawing(s) (when necessary as prescribed by 35 USC 113)							
	a.	. 🗆	Formal	Number of Sheets					
	b.	. 🗆	Informal	Number of Sheets					
4.	X	Oaf	Oath or Declaration						
	a.	. 🗷	Newly executed (c	original or copy) Unexecuted					
	b.	. 🗆	Copy from a prior	application (37 CFR 1.63(d)) (for continuation/divisional application only)					
	C.								
m Å	d. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).								
5. 6.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.							
# 6.		Con	Computer Program in Microfiche (Appendix)						
7.		Nuc	aleotide and/or Amin	o Acid Sequence Submission (if applicable, all must be included)					
FI S	a.		Paper Copy						
	b.		Computer Readabl	le Copy (identical to computer copy)					
#76 #16 #18	C.		Statement Verifying	g Identical Paper and Computer Readable Copy					
./				Accompanying Application Parts					
V8.	X	Assi	ignment Papers (co	ver sheet & document(s))					
9.		37 C	CFR 3.73(B) Statem	ent (when there is an assignee)					
10.		English Translation Document (if applicable)							
11.	X	Information Disclosure Statement/PTO-1449 Copies of IDS Citations							
12.		Preli	liminary Amendment						
13.	X	Ackn	nowledgment postca	rd					
14.	X	Certi	ificate of Mailing						
	ı		First Class E	Express Mail (Specify Label No.): EI748257910US					

Application Elements (Continued)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

A THE REAL PROPERTY AND A STATE OF THE PARTY A

B

Docket No. P01627

Total Pages in this Submission 166

15.	Certified Copy of Priority Document(s) (if foreign priority is claimed)					
16.	Additional Enclosures (please identify below):					
	*					

Accompanying Application Parts (Continued)

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P01627

Total Pages in this Submission 166

Fee Calculation and Transmittal

		CLAIMS A	S FILED					
For	#Filed	#Allowed	#Extra	Rate	Fee			
otal Claims	19	- 20 =	0	× \$18.00	\$0.00			
dep. Claims	1	- 3 =	0	x \$84.00	\$0.00			
ultiple Dependent Cl	laims (check if	applicable)]		\$0.00			
				BASIC FEE	\$740.00			
THER FEE (specify	purpose)				\$0.00			
				TOTAL FILING FEE	\$740.00			
Credit any overpayment. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Signature John E. Thomas Registration No. 34,070 Bausch & Lomb Incorporated								
× ×			One Roc	Bausch & Lomb Place hester, New York 14604-2701 ephone: 585/338-8969				

CERTIFICATE OF MAIL	Docket No.		
Applicant(s): Jay F. Kunz	P01627		
Serial No.	Filing Date	Examiner	Group Art Unit
Not Yet Assigned	December 06, 2001	Not Yet Assigned	Not Yet Assigned

Invention: Poly(2-Oxazoline) Biomedical Devices

I hereby certify that this New Utility Patent Application and its Attachments

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: U. S. Patent and Trademark Office, P O Box 2327, Box Patent Application, Arlington, VA 22202 on December 06, 2001.

Sharon L. Sechrist

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

EI748257910US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.